Julie Rubinstein, President and COO, has demonstrated a clear selling bias in her recent transactions involving Adaptive Biotechnologies Corporation (ADPT), with no buys recorded in her last 13 trades. Since mid-March 2026, Rubinstein has executed a series of sales totaling over $2.5 million, with individual transactions ranging from $25,121 to $271,986. These disposals were frequently accompanied by smaller acquisitions marked as "M" (likely option exercises), averaging approximately $96,429 per transaction earlier in the period before stabilizing around $107,028 in late March. The pattern suggests a methodical unwinding of positions, with sales occurring on nearly consecutive trading days—most notably a $269,127 sale on March 26 followed by a $271,986 transaction on March 25.
Rubinstein’s broader trading history reveals a long-term disposition toward reducing exposure to ADPT, with total sales exceeding $8.1 million against $2.8 million in buys across 54 reported transactions. The absence of recent purchases and the consistency of her selling activity—particularly the concentrated disposals in late March—indicate a sustained effort to liquidate holdings. While the "M"-coded transactions suggest she continues to receive equity compensation, her immediate subsequent sales imply a preference for converting those holdings to cash rather than maintaining or increasing her stake in the company. The transactions are notable for their regularity and size, with no single sale exceeding $300,000 but collectively representing a significant reduction in position.
AI-assisted summary